Johnson & Johnson beats Q2 sales estimates, raises FY outlook

Johnson & Johnson

Johnson & Johnson

JNJ

0.00


Overview

  • U.S. healthcare conglomerate's Q2 sales rose 6.6%, beating analyst expectations

  • Adjusted EPS for Q2 increased 4.7% to $2.90, beating analyst expectations

  • Company raised 2026 sales and adjusted EPS guidance after strong operational performance


Outlook

  • Johnson & Johnson raises 2026 reported sales guidance to $101.1 bln at midpoint

  • Company increases 2026 adjusted EPS guidance by $0.13 to $11.68 at midpoint

  • Johnson & Johnson expects continued momentum from innovation and pipeline approvals


Result Drivers

  • ONCOLOGY AND NEUROSCIENCE GROWTH - Co said operational sales growth was driven by oncology products such as DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and neuroscience drugs SPRAVATO and CAPLYTA

  • IMMUNOLOGY DECLINES OFFSET GAINS - Co said growth was partially offset by lower sales of STELARA and REMICADE in Immunology, as well as IMBRUVICA and ZYTIGA in Oncology

  • MEDTECH EXPANSION - Co said 3.6% operational growth in MedTech sales was driven by wound closure and biosurgery products in Surgery, electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics


Company press release: ID:nBwbsZrJXa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Sales

Beat

$25.31 bln

$25.05 bln (15 Analysts)

Q2 Adjusted EPS

Beat

$2.90

$2.85 (16 Analysts)

Q2 EPS

$2.27

Q2 Net Income

$5.53 bln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Johnson & Johnson is $264.00, about 4% above its July 14 closing price of $253.85

  • The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.